Case details

Merger control

Case reference

CCENT/2007/36 - INVERNESS/BIOSITE

Acquired

Biosite

Description

a biomedical diagnostics company with its headquarters in San Diego, California, that develops and markets diagnostic tests in the areas of cardiovascular diseases, drug detection and contagious diseases.

Acquiring

Inverness

Description

an undertaking with its headquarters in Waltham, Massachusetts, that produces and markets, on a worldwide basis, in vitro diagnostic products, in a variety of professional and consumer diagnostics, including immunological diagnostics in the field of cardiology, infectious diseases and women´s health. The undertaking also possesses a nutritional supplement division;

Sector

Extractive and manufacturing Industries

Activity (NACE)

C21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations

Applicable legislation

Art. 9(1)(a) (Law 18)

Notification thresholds

Market share

Type of merger

Horizontal

Cooperation with sector regulators

Status

Closed

Type of Investigation

Phase 1

AdC’s decision

Case description

Notified on 1 June 2007, with effect on 19 June 2007, this merger consists of the acquisition, by INVERNESS MEDICAL INNOVATIONS, INC (hereafter "INVERNESS"), of sole control of BIOSITE, INC. (hereafter "BIOSITE").

Timeline

2007-08-06

COMPETITION AUTHORITY approves acquisition, by INVERNESS MEDICAL INNOVATIONS, INC, of sole control of BIOSITE INC., which is active in the diagnostic test market in the areas of cardiovascular diseases, drug detection and infectious diseases

Top links

Case details